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In both arteries, fluorescence ligand binding in the double
knockouts was consistent with a “pure” population of the remaining
subtype, as shown by elimination of binding by the relevant selective
antagonist. Distribution of receptors on the cell surface and inside
cells was not affected by the absence of the other subtypes. However,
one difference was that the distribution of the alpha-1A-AR amongst
the smooth muscle cells was more heterogeneous than for alpha-1D-
AR. Repeating these experiments in wildtype or alpha-1B-KO mice
demonstrated that both alpha-1A-AR and alpha-1D-AR were present
and that eliminating them with selective competitors did not show a
dominance in the number of each subtype present, irrespective of
which was dominant in functional terms.
‘Pure’ alpha-1-AR-subtype pharmacology found in the double
knockouts provides quantitative standards. Alpha-1A-AR and alpha-
1D-AR produced additive responses, each dominating in different
vessels, and did not significantly compensate in knockout mice. Alpha-
1D-AR contributes to sensitivity to phenylephrine even in resistance
arteries. There was no correlation between the presence of a given
subtype as shownby fluorescent ligandbinding sites and its contribution
to vascular contraction: this suggests that the signalling process is more
critical than the quantitative presence of the receptor. Similar distribu-
tion of fluorescent binding in the double KOs and WT indicates that in
native SMC alpha-1-AR-subtypes do not influence each other's location.
In conclusion, alpha-1-subtypes donot interact but provide independent
alternative signals for autonomic regulation of the vasculature.
Acknowledgements: Support from the British Heart Foundation
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S14.5 The effects of Δ9-tetrahydrocannabinol on sympathetic
cotransmission in the mouse vas deferens
J.A.G. Kennard, A.R. Sachdev, J.S. Young, K.L. Brain (Department of
Pharmacology, University of Oxford)
The mouse vas deferens is a well established model system for
studying the effects of cannabinoids on sympathetic neuroeffector
junctions [1]. This tissue is also frequently used to study cotransmission,
as both noradrenaline (NA) and ATP are released from the nerve
terminal varicosities (NTVs). However, investigation for differing effects
of cannabinoids on the release and downstream actions of each of these
neurotransmitters when pharmacologically isolated has not been
carried out in the vas deferens. Therefore, we conducted experiments
using Δ9-tetrahydrocannabinol (Δ9-THC) to investigate this.
Vasa deferentia were excised from male Balb/C mice (7–10 weeks)
for use in contraction and confocal microscopy experiments. For
contraction studies, vasa were suspended in 5 mL organ baths with
electrical field stimulation (EFS) provided by two platinum ring
electrodes. The noradrenergic and purinergic components of contrac-
tion were isolated using α,β-methylene ATP (1 µM) and prazosin
(100 nM) respectively; drugswere added by pipette into the organ bath.
Δ9-THC (100 nM) caused a reduction in the peak amplitude of both
noradrenergic and purinergic neurogenic contractions (10 pulses,10 Hz,
0.5 ms width, supramaximal voltage) with a significant effect from
20min (P<0.01, n=4–5) and reaching amaximal effect by 30–40min.
Interestingly, Δ9-THC caused a greater reduction in the amplitude of
noradrenergic than purinergic contractions: at 40 min, noradrenergic
contractions showedanaverage72±14%reduction compared tovehicle
controls whereas purinergic contractions were reduced by 15±14%
only (P=0.01). In agreementwith previous studies, the effect ofΔ9-THC
upon neurogenic contractions was concentration-dependent and did
not have a significant effect upon contractions caused by the application
of the exogneous agonists phenylephrine (0.1–30 µM) and α,β-
methylene ATP (10 nM–1 µM). For experiments using a range of EFS
train lengths (1–200 pulses), Δ9-THC (100 nM) significantly increased
the peak area for noradrenergic contractions at 200 pulses (P<0.05,
n=6) with an average 134±37% increase in peak area compared to
vehicle controls. No significant effect was observed upon purinergic
contractions.
For imaging experiments, vasa were orthogradely filled with the
Ca2+ indicator Oregon Green 488 BAPTA-1 10 kDa dextran to identify
sympathetic terminals on the stage of a Leica NT confocal microscope
[2]. Upon imaging electrically-induced Ca2+ transients in NTVs, Δ9-
THC (100 nM) reduced the relative change in ΔF/F0 observed after a
single field stimulus, compared to vehicle controls (P<0.0005). On
average, Δ9-THC resulted in a 20±3% reduction in the relative change
of ΔF/F0 (P=0.0001), whereas vehicle produced no significant
change 1±3% increase (P>0.05).
These results show that Δ9-THC reduces the release of NA and ATP
from sympathetic nerves in the mouse vas deferens, possibly by
reducing Ca2+ influx into NTVs. The effect on NA appears to be
greater; considering this and the increase in contraction area, it is
tempting to speculate on an inhibitory action on the norepinerphrine
transporter type 1 (NET-1).
[1] Thomas, A., Pertwee, R.G. 2006. The bioassay of cannabinoids
using themouse isolated vas deferens. MethodsMol Med 123, 191–207.
[2] Brain, K.L., Bennett, M.R. 1997. Calcium in sympathetic
varicosities of mouse vas deferens during facilitation, augmentation
and autoinhibition. J Physiol 502, 521–536.
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S15. Linking emotional stress to autonomic function
S15.1 The activity of the sympathetic nervous system in conditions
characterized by high emotional stress
E. Lambert, T. Dawood, G. Lambert (Human Neurotransmitters
Laboratory, Baker IDI Heart and Diabetes Institute, Melbourne,
Victoria, Australia)
Psychological factors, including everyday stress, major life events
or the presence of depressive illness are now recognized as possible
“triggers” for clinical cardiovascular events. Disturbed sympathetic
nervous system (SNS) activity could possibly be one underlying
mechanism linking psychological stress and cardiovascular disease.
We tested whether subjects with panic disorder and major
depressive disorder (MDD) (but free of any cardiovascular conditions)
presentedwith abnormal SNS activity. Microneurographic recordings of
multi-unit MSNA in these subjects revealed normal rate of sympathetic
nervous activity. However, by applying the technique of single unit
MSNA recording (i.e., measuring single vasoconstrictor neuron activity)
in subjects with panic disorder and MDD, we noted a disturbed
sympathetic firing pattern in that there occurred a higher incidence of
multiple firing of vasoconstrictor neurones during a sympathetic burst
(increased salvoes). Such an irregular pattern of sympathetic nerve
firing may possibly be relevant to the increased cardiac risk as the
disturbed pattern of firing was paralleled by an increased release of
noradrenaline from the cardiac sympathetic nerves.
We further investigated the link between stress and sympathetic
nerve firing pattern in subjects with the metabolic syndrome and
hypertension, who commonly, report high level of stress. We
examined the SNS activity (multi-unit and single-unit MSNA) in
relation to their underlying psychological stress [assessed by the State
and Trait Anxiety score) and depression symptoms (assessed by using
the Beck Depression Inventory II (BDI)]. Multi-unit MSNA was not
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